Other languages Soligenix, Inc.

Equities

SNGX

US8342235053

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.415 ^USD	-2.81%		-3.71%	-45.19%

Apr. 25	Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa	CI
Apr. 15	Sector Update: Health Care Stocks Softer Late Afternoon	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa	Apr. 25
Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte? with the European Medicines Agency	Apr. 03
Soligenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 15
Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board	Feb. 08
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease	Jan. 08
Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis	Jan. 04
Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses	Jan. 02
Wall Street Set to Open Lower Friday as Investors Await Economic Data, Powell Speech	Dec. 01
Sector Update: Health Care Stocks Higher Late Afternoon	Nov. 30
Top MIdday Gainers	Nov. 30
Sector Update: Health Care Stocks Advance Thursday Afternoon	Nov. 30
Sector Update: Health Care	Nov. 30
Soligenix Says US FDA Cleared Application for Trial of Behcet's Disease Aphthous Ulcers Treatment	Nov. 30
Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's Disease	Nov. 30
Soligenix Seeks Acquisitions	Nov. 14
Soligenix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Soligenix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-21
Soligenix, Inc. Announces HyBryte(TM) Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment	23-08-10
Soligenix, Inc. Announces Timothy R. CotÃ© Resigns as Member of the Board of Directors	23-07-07
Soligenix Issued European Patent for Use of Dusquetide in Oral Mucositis	23-05-16

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Soligenix, Inc.

Equities

SNGX

US8342235053

Other languages

Filters